cilostazol has been researched along with probucol in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 16 (69.57) | 24.3611 |
| 2020's | 1 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Akutsu, H; Funada, J; Miyagawa, M; Sekiya, M; Watanabe, K | 1 |
| Schainfeld, RM | 1 |
| Hong, KW; Kim, CD; Lee, JH; Lee, WS; Park, SY; Rhim, BY | 1 |
| Douglas, JS | 1 |
| Kotosai, K; Mitani, K; Miyakoda, G; Nozako, M; Yabuuchi, Y; Yoshikawa, T | 1 |
| Jang, IJ; Kim, BH; Kim, KP; Kim, TE; Lim, KS; Shin, SG; Yu, KS | 1 |
| Choi, SH; Fitzerald, PJ; Honda, Y; Kang, WC; Kim, BK; Kim, SW; Ko, YG; Lee, BK; Lee, JH; Lee, M; Shim, WH | 1 |
| Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK | 1 |
| Bai, L; Chen, Y; Fan, J; Huang, B; Li, Y; Liu, E; Liu, R; Wang, Y; Waqar, AB; Zhao, S | 1 |
| Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y | 1 |
| Choi, SH; Chol Kang, W; Ko, YG; Kwon Lee, B; Shim, WH; Wook Kim, S | 1 |
| Bae, SS; Choi, BT; Hong, KW; Kim, JH; Shin, HK; Shin, YI | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Wang, Y; Zhao, S; Zhu, N | 1 |
| Byrne, RA; Guerra, E; Kastrati, A | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N | 1 |
| Chen, Y; Cho, GJ; Chung, HT; Joe, Y; Kim, HJ; Kim, SK; Pandiri, I; Park, J; Park, JW; Ryter, SW; Ryu, J | 1 |
| Hong, KS; Kwon, SU; Lee, J; Lee, JS; Oh, MS; Yu, KH | 1 |
| Hattori, A; Hayashi, A; He, P; Ide, K; Ide, S; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Maezawa, Y; Sakamoto, K; Shoji, M; Takemoto, M; Tokuyama, H; Yamaga, M; Yokote, K | 1 |
| Kim, YJ; Kwon, SU; Lee, J; Seo, WK | 1 |
| Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S | 1 |
| Ihara, M; Saito, S | 1 |
| Ge, J; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Oh, BH; Park, JE; Sung, J | 1 |
3 review(s) available for cilostazol and probucol
| Article | Year |
|---|---|
Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature.
Topics: Animals; Blood Vessels; Brachytherapy; Cilostazol; Clopidogrel; Constriction, Pathologic; Drug Delivery Systems; Endothelium, Vascular; Genetic Therapy; Heparin, Low-Molecular-Weight; Humans; Plastic Surgery Procedures; Platelet Aggregation Inhibitors; Probucol; Stents; Tetrazoles; Ticlopidine; Vasodilation; Vasodilator Agents | 2002 |
Pharmacologic approaches to restenosis prevention.
Topics: Angioplasty, Balloon, Coronary; Cilostazol; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Drug Therapy, Combination; Humans; ortho-Aminobenzoates; Pioglitazone; Platelet Aggregation Inhibitors; Probucol; Risk Factors; Stents; Tetrazoles; Thiazolidinediones; Trapidil; Treatment Outcome | 2007 |
Pharmacological inhibition of coronary restenosis: systemic and local approaches.
Topics: Anti-Bacterial Agents; Antioxidants; Cilostazol; Coronary Restenosis; Drug Delivery Systems; Drug-Eluting Stents; Humans; ortho-Aminobenzoates; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Probucol; Sirolimus; Tetrazoles; Tubulin Modulators; Vasodilator Agents | 2014 |
9 trial(s) available for cilostazol and probucol
| Article | Year |
|---|---|
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Cilostazol; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphodiesterase Inhibitors; Probucol; Prospective Studies; Recurrence; Stents; Tetrazoles; Treatment Outcome | 1998 |
Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Biotransformation; Cilostazol; Cross-Over Studies; Drug Interactions; Humans; Korea; Male; Platelet Aggregation Inhibitors; Probucol; Tetrazoles; Young Adult | 2009 |
Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Biomarkers; Cilostazol; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Inflammation Mediators; Lipids; Male; Platelet Aggregation Inhibitors; Probucol; Republic of Korea; Research Design; Stents; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug Therapy, Combination; Endothelium, Vascular; Female; Health Behavior; Hemodynamics; Humans; Hypercholesterolemia; Life Style; Lipids; Male; Middle Aged; Platelet Aggregation Inhibitors; Probucol; Prospective Studies; Stroke, Lacunar; Tetrazoles; Vasodilation | 2014 |
Effects of combination therapy with cilostazol and probucol versus monotherapy with cilostazol on coronary plaque, lipid and biomarkers: SECURE study, a double-blind randomized controlled clinical trial.
Topics: Anticholesteremic Agents; Biomarkers; Bronchodilator Agents; Cilostazol; Coronary Artery Disease; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Inflammation Mediators; Lipids; Male; Middle Aged; Probucol; Prognosis; Tetrazoles; Ultrasonography, Interventional | 2014 |
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
Topics: Adult; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cognition Disorders; Double-Blind Method; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; International Cooperation; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Probucol; Stroke; Tetrazoles; Time Factors; Treatment Outcome; Young Adult | 2016 |
Design and Rationale of the Intima-Medial Thickness Sub-Study of the PreventIon of CArdiovascular Events in iSchemic Stroke Patients with High Risk of Cerebral hemOrrhage (PICASSO-IMT) Study.
Topics: Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Cerebral Hemorrhage; Cilostazol; Clinical Protocols; Double-Blind Method; Humans; Predictive Value of Tests; Probucol; Prospective Studies; Republic of Korea; Research Design; Risk Factors; Stroke; Tetrazoles; Time Factors; Treatment Outcome | 2017 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Philippines; Probucol; Republic of Korea; Stroke; Treatment Outcome | 2018 |
Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study.
Topics: Anticholesteremic Agents; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Cilostazol; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Probucol; Time; Treatment Outcome | 2021 |
11 other study(ies) available for cilostazol and probucol
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Beneficial synergistic effects of concurrent treatment with cilostazol and probucol against focal cerebral ischemic injury in rats.
Topics: Animals; Antioxidants; Apoptosis; Biomarkers; Brain Ischemia; Caspase 3; Cerebral Infarction; Chemotaxis, Leukocyte; Cilostazol; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Peroxidase; Poly(ADP-ribose) Polymerases; Probucol; Rats; Rats, Sprague-Dawley; Superoxides; Telencephalon; Tetrazoles; Treatment Outcome; Tyrosine | 2007 |
Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cilostazol; Diet, Atherogenic; Drug Combinations; Drug Evaluation, Preclinical; Male; Mice; Mice, Knockout; Probucol; Receptors, LDL; Tetrazoles | 2008 |
Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia.
Topics: Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Drug Therapy, Combination; Hypercholesterolemia; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Probucol; Tetrazoles | 2011 |
Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Cholesterol, Dietary; Cilostazol; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Male; Platelet Aggregation Inhibitors; Probucol; Rabbits; Tetrazoles | 2013 |
Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Brain Injuries; Brain Ischemia; CD11b Antigen; Cerebral Cortex; Chemokine CCL2; Cilostazol; Disease Progression; Drug Therapy, Combination; Glial Fibrillary Acidic Protein; Hypercholesterolemia; Male; Mice, Inbred C57BL; Mice, Knockout; Microglia; Probucol; RNA, Messenger; Tetrazoles; Treatment Outcome | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Immunohistochemistry; Lipids; Probucol; Pyrroles; Rabbits; Tetrazoles | 2014 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hypercholesterolemia; Inflammation; Lipids; Male; Oxidation-Reduction; Oxidative Stress; Probucol; Rabbits; Tetrazoles | 2015 |
Synergistic Effects of Cilostazol and Probucol on ER Stress-Induced Hepatic Steatosis via Heme Oxygenase-1-Dependent Activation of Mitochondrial Biogenesis.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Cells, Cultured; Cilostazol; Disease Models, Animal; Drug Synergism; Endoplasmic Reticulum Stress; Heme Oxygenase-1; Hep G2 Cells; Hepatocytes; Humans; Liver; Male; Mice; Mice, Inbred C57BL; Mitochondria; Non-alcoholic Fatty Liver Disease; Probucol; Tetrazoles; Tunicamycin | 2016 |
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilostazol; Cytoprotection; Disease Models, Animal; Female; Kidney Diseases; Lipopolysaccharides; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NADPH Oxidase 4; NF-kappa B; Oxidative Stress; Phosphorylation; Podocytes; Probucol; Signal Transduction; Tetrazoles | 2017 |
[Drug Repositioning for Alzheimer's Disease].
Topics: Alzheimer Disease; Cilostazol; Dabigatran; Drug Repositioning; Humans; Insulin; Probucol; Telmisartan | 2019 |